Author

C. Morrissey

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Deep learning-based histologic classifiers enable molecular subtyping of metastatic prostate cancer.

Metastatic prostate cancer is a clinically and molecularly heterogeneous disease. Under the selective pressure of androgen receptor (AR)-directed therapies, resistant phenotypes frequently emerge, posing significant diagnostic and therapeutic challenges. Neuroendocrine prostate cancer (NEPC) is a clinically important p...

Zhi-Jun Chen, Erolcan Sayar, D. Guevara et al. · JCI Insight · 0 citations

Open access Sep 2026

Evolution and heterogeneity of lethal metastatic bladder cancer subtypes.

Histological variation is a prognostic feature of metastatic urothelial cancer1-3, but its evolutionary trajectory remains poorly defined. We developed a metastatic bladder cancer rapid autopsy programme enriched in histological subtypes4 to profile individuals with terminal disease. Here by reconstructing the evolutio...

P. Itagi, Samantha L. Schuster, Sonali Arora et al. · Nature · 0 citations

Open access Aug 2026

Combined BET bromodomain and DNMT inhibition targets critical survival pathways in transdifferentiated prostate cancer.

Lineage plasticity, or transdifferentiation, is increasingly recognized as a resistance mechanism to androgen receptor (AR) inhibition in prostate cancer. Lineage plasticity is characterized by loss of AR signaling and epithelial differentiation, along with activation of stemness-associated pathways, epithelial-mesench...

W. Storck, Diana Flores, A. Kumaraswamy et al. · JCI Insight · 0 citations